6533b82efe1ef96bd1292926
RESEARCH PRODUCT
Whole-Body Magnetic Resonance Imaging: Current Role in Patients with Lymphoma.
Roberto LagallaDomenico AlbanoMassino GaliaEmanuele GrassedonioFederico MidiriLudovico La GruttaSilvia AlbanoGiuseppe MicciGiuseppe Lo ReC. Pattisubject
Medicine (General)medicine.medical_specialtydiffusion-weighted imagingClinical BiochemistryWhole body imagingLymphoproliferative disorderslymphomaReviewwhole-body imaging030218 nuclear medicine & medical imagingIonizing radiation03 medical and health sciencesR5-9200302 clinical medicinehemic and lymphatic diseasesmedicinemagnetic resonance imagingmedicine.diagnostic_testbusiness.industryCancerMagnetic resonance imagingstagingmedicine.diseaseLymphomaPositron emission tomography030220 oncology & carcinogenesisRadiologybusinessDiffusion MRIdescription
Imaging of lymphoma is based on the use of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) and/or contrast-enhanced CT, but concerns have been raised regarding radiation exposure related to imaging scans in patients with cancer, and its association with increased risk of secondary tumors in patients with lymphoma has been established. To date, lymphoproliferative disorders are among the most common indications to perform whole-body magnetic resonance imaging (MRI). Whole-body MRI is superior to contrast-enhanced CT for staging the disease, also being less dependent on histology if compared to 18F-FDG-PET/CT. As well, it does not require exposure to ionizing radiation and could be used for the surveillance of lymphoma. The current role of whole-body MRI in the diagnostic workup in lymphoma is examined in the present review along with the diagnostic performance in staging, response assessment and surveillance of different lymphoma subtypes.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-05-31 | Diagnostics (Basel, Switzerland) |